OP004 Early combined immunosuppression for the management of Crohn's disease: A community-based cluster randomized trial
Reena Khanna(University of Toronto), Brian G. Feagan(Western University), Remo Panaccione(University of Calgary), Séverine Vermeire(KU Leuven), Joan C. Morris(Robarts Clinical Trials), William J. Sandborn(University of San Diego), G.R. Greenberg, Margaret K. Vandervoort(Western University), Geert D’Haens(Amsterdam University Medical Centers), Brian Bressler(University of British Columbia), Larry Stitt(Western University), Guangyong Zou(Western University), Barrett G. Levesque(University of California San Diego), Asaf Bitton(Brigham and Women's Hospital), Donald MacIntosh(Dalhousie University), Pierre Paré(Université Laval)
Cited by 19
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k